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A previous study had shown that the expression of gp90, a stage-specific surface glycoprotein of Trypanosoma
cruzi metacyclic trypomastigotes, is inversely correlated with the parasite’s ability to invade mammalian cells.
By using antisense oligonucleotides complementary to a region of the gp90 gene implicated in host cell
adhesion, we investigated whether the selective inhibition of gp90 synthesis affected the capacity of metacyclic
forms to enter target cells. Parasites were incubated for 24 h with 20 mM PS1, a phosphorothioate oligonu-
cleotide based on a sequence of the gp90 coding strand; PS2, the antisense counterpart of PS1; or PO2, the
unmodified version of PS2 containing phosphodiester linkages, and the expression of surface molecules was
analyzed by flow cytometry and immunoblotting using specific monoclonal antibodies. PS2 but not PS1 or PO2
inhibited the expression of gp90. Inhibition by PS2 was dose dependent. Northern blot analysis revealed that
steady-state gp90 mRNA levels were diminished in PS2-treated parasites compared to untreated controls.
Treatment with PS2 did not affect the expression of other metacyclic stage surface glycoproteins involved in
parasite-host cell interaction, such as gp82 and the mucin-like gp35/50. Expression of gp90 was also inhibited
by other phosphorothioate oligonucleotides targeted to the gp90 gene (PS4, PS5, PS6, and PS7) but not by PS3,
with the same base composition as PS2 but a mismatched sequence. Parasites treated with PS2, PS4, or PS5
entered HeLa cells in significantly higher numbers than untreated controls, whereas the invasive capacity of
PS1- and PS3-treated parasites was unchanged, confirming the inverse association between infectivity and
gp90 expression.
A critical step for the establishment of infection by Trypano-
soma cruzi, the agent of Chagas’ disease, is the invasion of host
cells by metacyclic trypomastigotes, the developmental forms
from the insect vector. We have found in a previous study that
gp90, a metacyclic stage-specific surface glycoprotein, is differ-
entially expressed in different T. cruzi strains and that the
parasite’s ability to invade target cells is inversely correlated
with gp90 expression (17). gp90 binds to mammalian cells in a
receptor-mediated manner without triggering Ca21 signal, a
requirement for T. cruzi entry into target cells (6, 12, 21, 25), in
contrast to the interaction mediated by gp82, the metacyclic
stage surface glycoprotein implicated in host cell invasion (15),
which induces Ca21 mobilization in both the parasite and the
target cell (6, 17).
Recent studies aimed at defining the function of protozoan
parasite components have used approaches such as gene dis-
ruption by homologous recombination and antisense RNA. By
gene knockout, the surface molecules of malaria parasites cir-
cumsporozoite protein (CS) and thrombospondin-related
anonymous protein (TRAP) have been shown to play a critical
role in development in mosquitoes (11) and for infection of the
liver (20). In Toxoplasma gondii, the targeted inhibition of
nucleoside triphosphate hydrolase by antisense RNA blocked
parasite proliferation (13). The T. cruzi gp90 gene is not ame-
nable to gene knockout by homologous recombination because
it is present in multiple copies in the genome (8), but the
antisense strategy appears to be an interesting possibility. An-
tisense oligodeoxynucleotides designed to function as inhibi-
tors of specific mRNAs and made resistant to nucleases by
introduction of modifications such as phosphorothioate link-
ages have been used for gene inhibition in mammalian cells in
tissue culture assays and in vivo studies (1, 23). Using such an
approach, antiparasitic activities of antisense oligonucleotides
towards obligatory intracellular protozoans have been re-
ported. By treating macrophages infected with Leishmania
amazonensis for 24 h with phosphorothioate oligonucleotide
targeted to the miniexon sequence present at the 59 end of
every parasite mRNA, cure of about 30% of infected macro-
phages was observed (14). Rapaport et al. (16) demonstrated
that the dihydrofolate reductase-thymidylate synthase gene of
Plasmodium falciparum is a good target for sequence-depen-
dent inhibition of plasmodial growth by exogenously adminis-
tered phosphorothioate oligonucleotides.
In the present study, we used antisense oligonucleotides
targeted to gp90 gene sequences in addition to control oligo-
nucleotides to determine the effect of this treatment on meta-
cyclic trypomastigote gp90 expression and on the the parasite’s
ability to enter host cells.
MATERIALS AND METHODS
Oligodeoxynucleotides. The following phosphorothioate oligonucleotides were
used: PS1, based on a sequence of the gp90 coding strand (59-GTGGCGTCG
GTGACC ATCGAAGAG-39); PS2, corresponding to a sequence complemen-
tary to PS1 (59-CTCTTC GATGGTCACCGACGCCAC-39); PS3, with the same
base composition as PS2 but with a scrambled sequence (59-TTCCCTGTGTA
GGCCAGCCCAACC-39); and PS4 PS5, PS6, and PS7, complementary to dif-
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ferent sequences of the g90 coding strand, with the following base compositions,
respectively: 59-TGTGAAGTTGTGGCTCAAGGATAC-39, 59-AGCGTCCGC
ACTCGGAGCCTCTTC-39, 59-TTGGTATTCTTTCCCCGG-39, and 59-GCCA
TCAACGTACACCGAGCTCTTGTTACC-39. In addition, PO2, the unmodi-
fied version of PS2 containing phosphodiester linkages, was tested.
Parasites, mammalian cells, and cell invasion assay. T. cruzi strain G (26) was
used throughout this study. Parasites were maintained alternately in mice and in
liver infusion tryptose medium (LIT) containing 5% fetal calf serum. Metacyclic
trypomastigotes harvested from LIT cultures at the stationary growth phase were
purified by passage through a DEAE-cellulose column as described (22). HeLa
cells, human carcinoma-derived epithelial cells, were grown at 37°C in Dulbec-
co’s minimal essential medium supplemented with 10% fetal calf serum, strep-
tomycin (100 mg/ml), and penicillin (100 U/ml) in a humidified 5% CO2 atmo-
sphere. Experiments for mammalian cell invasion by T. cruzi were performed
essentially as previously described (27).
MAbs. The following monoclonal antibodies (MAbs) were used: 1G7, 3F6,
and 10D8, directed to T. cruzi surface glycoproteins gp90, gp82, and the mucin-
like gp35/50, respectively (15, 27, 28). Unrelated MAb 1C3, directed to Leish-
mania amazonensis gp63 (3), was kindly provided by Clara Lucia Barbieri,
Universidade Federal de Sa˜o Paulo.
Purification of native and recombinant gp90. To purify the native gp90, par-
asite extracts were prepared by treating metacyclic trypomastigotes with 0.5%
Nonidet P-40 in the presence of protease inhibitors. After centrifugation at
12,000 3 g for 5 min, the supernatant was collected and mixed with the antibody
affinity column prepared by coupling MAb 1G7 to CNBr-activated Sepharose 4B
(Amersham/Pharmacia). After 2 h at room temperature under constant shaking,
the resin was packed in a 10-ml plastic syringe and washed several times with
phosphate-buffered saline (PBS). The bound antigen was eluted with 0.1 M
glycine, pH 2.8, neutralized, dialyzed against double-distilled water, vacuum
dried, and stored at 220°C until use. To purify the recombinant protein con-
taining the gp90 C-terminal domain in fusion with glutathione S-transferase
(GST) (8), suspensions of isopropyl-b-D-thiogalactopyranoside (IPTG) induced
Escherichia coli were washed in PBS, sonicated for 10 min (1-min pulse at 30-s
intervals), and centrifuged at 12,000 3 g for 10 min at 4°C. The precipitate was
resuspended in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer, boiled, and subjected to SDS-PAGE. The gels were
treated with iced 250 mM KC1 to visualize the bands on a black background. By
using molecular size markers ranging from 94 to 14 kDa (Amersham Pharmacia)
as a reference, the band of high intensity and of the expected size for the
recombinant protein was excised and electroeluted as described (24), using a
buffer containing 25 mM Tris-HC1, 192 mM glycine-HCl, and 20% methanol.
The electroeluted sample was dialyzed against 10 mM ammonium bicarbonate
for 24 h and thereafter against distilled water for another 24 h. The purity of the
isolated protein was assessed by staining the SDS-PAGE gel with Coomassie
blue and by immunoblotting using MAb 1G7.
Immunoblotting. Parasites were lysed with 1.0% nonionic detergent Nonidet
P-40, the lysates were dissolved in loading buffer, and equal amounts of the
parasite extract (;10 mg) were loaded into SDS–10% PAGE gels. After elec-
trophoresis under reducing conditions, the proteins were transferred to nitrocel-
lulose membranes. The equal loading of parasite samples was monitored by
staining the nitrocellulose membranes with 0.1% (wt/vol) Ponceau S in 10%
acetic acid. Following blockage with PBS containing 7.5% defatted milk (PBS-
milk), the membranes were incubated for 1 h at room temperature with anti-T.
cruzi MAbs diluted in PBS-milk. After several washes in PBS containing 0.05%
Tween 20, the membranes were further incubated with anti-mouse immunoglob-
ulin G (IgG) conjugated to peroxidase. The final reaction was revealed with
diaminobenzidine and H2O2 (27).
RNA purification and Northern blot analysis. Purified metacyclic trypomas-
tigotes were lysed with 1 ml of Trizol reagent (Gibco-BRL). Following complete
dissolution and addition of 0.2 ml of chloroform, the parasite preparation was
centrifuged for 15 min at 14,000 3 g to recover the aqueous phase. An equal
volume of isopropyl alcohol was added to the aqueous phase to precipitate the
total RNA overnight at 220°C. The precipitate was washed with 70% ethanol
and resuspended in RNase-free water. For Northern blot analysis, equivalent
amounts of RNA purified from untreated and oligonucleotide-treated parasites
were denatured with 50% formamide and 2.2 M formaldehyde and subjected to
electrophroresis in a 1.0% agarose gel containing formaldehyde. After staining
with ethidium bromide, the RNA was blotted onto a nylon membrane (Life
Technologies) in 203 SSC (13 SSC is 0.15 M NaCl and 0.015 M sodium citrate)
and immobilized on the filter by UV irradiation. The membrane was prehybrid-
ized in 50% formamide–53 SSC–53 Denhardt’s solution–0.5% SDS–5 mM
EDTA– 0.1 mg of tRNA per ml at 42°C for 2 h and then hybridized overnight at
the same temperature with 32P-labeled probe which consisted of the insert of the
gp90 cDNA clone (8 or b-tubulin. Following hybridization, the membrane was
washed in 23 SSC containing 0.1% SDS at 65°C three times for 30 min each and
exposed to X-ray film (Hyperfilm-MP; Amersham).
Inhibition of binding of native gp90 to HeLa cells with the recombinant
protein. HeLa cells (3 3 104) placed in 96-well microtiter plates (Costar) were
grown overnight at 37°C. After fixation with 4% paraformaldehyde in PBS, the
cells were washed with PBS and blocked with PBS containing 10% fetal calf
serum (FCS-PBS) for 1 h at room temperature. The cells were then incubated for
1 h at 37°C with the native gp90 (20 mg/ml) in FCS-PBS in the absence or
presence of various concentrations of the recombinant protein fused to GST.
Controls included HeLa cells incubated with gp90 in the presence of GST or
J18b, the GST-fused recombinant protein containing the C-terminal domain of
gp82 (19). After washes in PBS, the HeLa cells were sequentially incubated for
1 h at 37°C with MAb 1G7 diluted in FCS-PBS and anti-mouse IgG conjugated
to peroxidase. Following washes in PBS, the bound enzyme was revealed using
o-phenylenediamine as detailed (18).
Flow cytometry. Live metacyclic trypomastigotes (2 3 107 cells) were incu-
bated for 1 h on ice with MAbs directed to metacyclic stage surface molecules or
with unrelated MAb 1C3. After washes in PBS, the parasites were fixed with 2%
paraformaldehyde in PBS for 30 min. The fixative was washed out, and the
parasites were incubated with fluorescein-labeled goat anti-mouse IgG for 1 h at
room temperature. Following two more washes, the number of fluorescent par-
asites was estimated with a Becton Dickinson cytometer.
RESULTS
Antisense oligonucleotides based on sequences of a cDNA
clone encoding the C-terminal domain of gp90 which contains
the host cell binding site. The sequence of gp90 that is cur-
rently known is that deduced from a cDNA clone correspond-
ing to the C-terminal domain of the molecule (8). On the basis
that this sequence, which is a member of a family of related
sequences present in the parasite genome, encodes a recom-
binant protein that reacts with an MAb as well as with mono-
specific polyclonal antibodies directed to the native gp90 (8),
we presumed that it is represented in the gp90 gene(s) actually
expressed in metacyclic trypomastigotes. To determine whether
the cDNA-encoded recombinant protein which binds to mam-
malian cells in the same manner as the native gp90 (17) was
capable of inhibiting the adhesion of gp90 to host cells, assays
were carried out by incubating HeLa cells for 1 h at 37°C with
the native gp90 at 20 mg/ml in the absence or presence of
various concentrations of gp90 recombinant protein (r-gp90)
fused to GST. As controls, HeLa cells were incubated with the
native gp90 plus GST or J18b at 40 mg/ml the (J18b is the
GST-fused recombinant protein containing the C-teminal do-
main of metacyclic stage surface molecule gp82, which binds to
HeLa cells through a sequence that is not represented in r-
gp90) (10). Binding of gp90 to HeLa cells was revealed by
MAb 1G7, which recognizes the native molecule but not r-
gp90. As shown in Fig. 1, r-gp90 inhibited the binding of native
gp90 to HeLa cells in a dose-dependent fashion, whereas GST
and J18 did not show any inhibitory effect. Reaction of parallel
wells of the enzyme-linked immunosorbent assay plate with
anti-GST antibody revealed the binding of r-gp90 and J18 to
HeLa cells (data not shown).
To design the antisense oligonucleotides targeted to the
gp90 gene, we selected sequences displaying low similarity with
those of the gp82 gene and sequences common to both genes
(Fig. 2A). The target and the various oligonucleotides contain-
ing phosphorothioate linkages used in this study are schemat-
ically represented in Fig. 2B.
Expression of gp90 reduced in metacyclic trypomastigotes
treated with antisense oligonucleotides targeted to the corre-
354 MA´LAGA AND YOSHIDA INFECT. IMMUN.
sponding gene. To determine whether the expression of gp90
could be blocked by the antisense approach, 4 3 107 purified
metacyclic trypomastigotes were incubated for 24 h at 28°C in
0.2 ml of LIT medium in absence or presence of 20 mM PS1,
a phosphorothioate oligonucleotide based on a sequence of the
gp90 coding strand; PS2, the antisense counterpart of PS1; or
PO2, the unmodified version of PS2 containing phosphodiester
linkages. Upon treatment with the different oligonucleotides,
the parasites were processed for immunoblot detection of the
major metacyclic stage surface glycoproteins gp90, gp82, and
gp35/50 using specific MAbs. As shown in Fig. 3A, the expres-
sion of gp90 was markedly diminished in PS2-treated metacy-
clic forms compared to untreated and PS1- or PO2-treated
parasites. When quantified by densitometry, the intensity of
the gp90 band in PS2-treated parasites was ;50% lower than
that of the controls. The expression of gp82 or gp35/50 was not
significantly affected by any of these oligonucleotides (Fig. 3B).
PS2 inhibited gp90 expression in a dose-dependent manner
(Fig. 3C). At 5 mM, the inhibitory effect of PS2 was minimal
and increased progressively at 10 and 20 mM. Further reduc-
tion in gp90 levels was not apparent in parasites treated with 40
mM PS2. This inhibitory effect of PS2 was specific inasmuch as
the intensity of the gp35/50 bands in the same blot was unal-
tered (Fig. 3C). When metacyclic forms were treated with
oligonucleotide PS6 or PS7 at 20 mM (Fig. 2), with sequences
common to the gp90 and gp82 genes (matching 94 and 89%,
respectively), the expression of both molecules was reduced
(Fig. 3D).
Next, we determined the amounts of gp90, gp82, and
gp35/50 on the parasite surface. Live metacyclic forms, un-
treated or treated with oligonucleotide, were incubated with
unrelated or specific MAb. After washes, fixation with para-
formaldehyde, and reaction with fluorescein-conjugated anti-
mouse IgG, the parasites were analyzed by flow cytometry. The
levels of gp90 but not of gp82 or gp35/50 on the parasite
surface were reduced in PS2-treated metacyclic forms (Fig. 4).
Inhibition by PS2 was dose dependent (Fig. 5). In PS1-treated
parasites, the expression of the three surface glycoproteins was
unaltered (data not shown).
To further confirm the sequence-specific gp90 gene inhibi-
tion, the following additional phosphorothioate oligonucleo-
tides were tested: PS3, with the same base composition as PS2
but mismatched sequence, and PS4 and PS5, which are com-
plementary to sequences located upstream and downstream of
FIG. 1. Adhesion of metacyclic trypomastigote surface glycopro-
tein gp90 to host cells is inhibited by the recombinant protein contain-
ing the C-terminal domain of the molecule. The assay was carried out
as described in the text by incubating HeLa cells for 1 h at 37°C with
native gp90 at 20 mg/ml in the absence or presence of the indicated
concentrations of r-gp90. HeLa cells incubated with gp90 plus GST or
J18b, the recombinant protein containing the C-teminal domain of
gp82, served as controls. The binding of gp90 was revealed by MAb
1G7, which recognizes the native molecule but not the recombinant
protein. Representative results of one of three experiments are shown.
Values are the means 6 standard deviation (SD) of triplicates.
FIG. 2. Oligonucleotides and target gp90 gene encoding the T.
cruzi metacyclic trypomastigote surface glycoprotein. (A) Nucleotide
sequence of gp90 analyzed in this study, aligned with that of gp82 for
comparison. The regions on which the oligonucleotides complemen-
tary to gp90 were based are indicated (PS2, PS4, PS5, PS6, and PS7).
(B) Schematic representation of the currently known portion of the
gp90 gene, which corresponds to that encoding the C-terminal domain
of the molecule. The arrows represent the various phosphorothioate
oligonucleotides (not drawn to scale): PS1, based on a sequence of the
gp90 coding strand; PS2, the antisense counterpart of PS1; PS3, with
the same base composition as PS2 but mismatched sequence; and PS4
to PS7, complementary to different gp90 sequences.
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PS1, respectively (Fig. 2). Metacyclic trypomastigotes were in-
cubated for 24 h with 20 mM PS2, PS3, PS4, or PS5, and gp90
expression was analyzed by flow cytometry using MAb 1G7. As
shown in Fig. 6, gp90 levels were significantly decreased in PS4-
and PS5-treated metacyclic forms, in a manner similar to the
effect obtained with PS2, whereas gp90 expression in PS3-
treated parasites remained unchanged.
Incubation of metacyclic trypomastigotes with any of these
oligonucleotides for 5 to 6 h did not result in significant inhi-
bition of gp90 levels. A longer incubation time (48 h) with the
antisense oligonucleotide was not more effective than 24 h of
incubation in reducing the expression of gp90. This may be
associated with the slow turnover of gp90. We treated the
parasites for 30 min at 37°C with proteinase K, which greatly
reduces the expression of gp90. After washes in PBS, the par-
asites were maintained in culture medium, and at various times
samples were taken to determine the recovery of gp90 expres-
sion. Even at 20 h posttreatment, gp90 expression did not
reach pretreatment levels (data not shown), indicating that its
turnover rate is low. Attempts to improve the delivery of oli-
gonucleotide by using cationic lipids, which reportedly enhance
cellular uptake of phosphorothioate oligonucleotides (4),
failed to augment the efficiency in inhibiting gp90 expression
(data not shown).
Antisense oligonucleotide targeted to gp90 is taken up by
metacyclic trypomastigotes and decreases the steady-state lev-
els of gp90 mRNA. To ascertain the incorporation of the oli-
FIG. 3. Antisense oligonucleotide PS2 inhibits gp90 expression in
T. cruzi metacyclic trypomastigotes. Parasites, either untreated (—) or
treated for 24 h with PS1, a phosphorothioate oligonucleotide based
on a sequence of the gp90 coding strand; PS2, the antisense counter-
part of PS1; or PO2, the unmodified version of PS2 containing phos-
phodiester linkages were processed for immunoblotting. (A) MAb
directed to gp90; (B) MAbs directed to gp82 and gp35/50. Note the
specific inhibition of gp90 expression by PS2. (C) Parasites, untreated
(—) or treated with the indicated concentrations of PS2, were analyzed
by immunobloting using MAbs to gp90 and gp35/50. Note that the
expression of gp90 was reduced with increasing doses of PS2, whereas
that of gp35/50 remained unaltered. The difference in the intensity of
the gp35/50 bands in panels B and C is due to the use of different
batches of anti-gp35/50 MAb. (D) Parasites, untreated (—) or treated
with antisense oligonucleotide PS6 or PS7, with sequences common to
gp90 and gp82 genes, respectively, were processed for immunoblotting
with MAbs to gp90 or gp82, respectively.
FIG. 4. gp90 levels on the surface of T. cruzi metacyclic trypomas-
tigotes are selectively reduced by the antisense oligonucleotide PS2.
Parasites, untreated or treated with PS2, a phosphorothioate oligonu-
cleotide complementary to a sequence of the gp90 coding strand, were
incubated with (A) unrelated MAb 1C3, directed to Leishmania gp63,
(B) anti-gp90 MAb 1G7, (C) anti-gp82 MAb 3F6, or (D) anti-gp35/50
MAb 10D8. After paraformaldehyde fixation and reaction with fluo-
rescein-labeled anti-mouse IgG, the parasites were analyzed by flow
cytometry.
FIG. 5. Dose-dependent inhibition of gp90 expression by treatment
of T. cruzi metacyclic trypomastigotes with antisense oligonucleotide
PS2. Parasites were treated with the indicated concentrations of PS2,
and the levels of gp90 on their surface were compared with those of
untreated controls by flow cytometry using anti-gp90 MAb 1G7.
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gonucleotide, the parasites were incubated for 20 h with vari-
ous concentrations of the fluorescein-labeled version of PS2,
fixed with paraformaldehyde, washed in PBS, and analyzed by
flow cytometry. As shown in Fig. 7A, the intensity of fluores-
cence was higher in PS2-treated parasites than in untreated
controls and increased with increasing PS2 concentration. As-
says performed with fluorescein-labeled PS6 showed essen-
tially the same results (data not shown). Staining was more
intense in the parasite nucleus (data not shown).
In experiments to determine the steady-state levels of the
transcripts corresponding to gp90, total RNA was extracted
from PS2-treated and untreated parasites for Northern blot
analysis. We found that gp90 mRNA was diminished in PS2-
treated parasites compared to untreated controls, whereas
b-tubulin mRNA was unaffected (Fig. 7B).
Infectivity of metacyclic trypomastigotes increases upon
treatment with antisense oligonucleotides targeted to the gp90
gene. To investigate the effect of decrease in gp90 expression
on parasite infectivity, cell invasion assays were performed with
metacyclic trypomastigotes subjected to 24 h of treatment with
the various oligonucleotides. Parasites treated with PS2, PS4,
or PS5 invaded HeLa cells in significantly higher numbers than
untreated controls (Fig. 8). By contrast, the infectivity of me-
tacyclic forms treated with PS1 or PS3 remained unchanged
(Fig. 8).
DISCUSSION
Our results suggest that the infectivity of T. cruzi metacyclic
trypomastigotes is downregulated by the surface glycoprotein
gp90. By treating metacyclic forms with antisense phosphoro-
thioate oligonucleotides complementary to sequences of the
gp90 gene, the gp90 levels on the parasite surface were re-
duced (Fig. 3 to 6) and the parasite ability to invade host cells
was significantly increased (Fig. 8). Such effects were not ob-
served when the parasites were treated with sense or mis-
matched oligonucleotides, indicating that the inhibition by an-
tisense oligonucleotides is sequence specific. This finding is
compatible with our previous observation that T. cruzi strains
expressing high gp90 levels are poor invaders of mammalian
cells, whereas gp90 is barely detectable in highly invasive
strains (17).
It should be noted that the expression of gp35/50, also
present on the T. cruzi surface, was not affected by the anti-
FIG. 6. gp90 sequence-specific antisense oligonucleotides PS4 and
PS5 affect T. cruzi metacyclic trypomastigote gp90 expression in the
same manner as PS2. Parasites, untreated or treated with (A) PS2, (B)
PS3, with a mismatched PS2 sequence, (C) PS4, or (D) PS5, which are
complementary to gp90 sequences flanking PS1 (Fig. 2), were incu-
bated with the anti-gp90 MAb 1G7. After paraformaldehyde fixation
and reaction with fluorescein-labeled anti-mouse IgG, the parasites
were analyzed by flow cytometry.
FIG. 7. Incorporation of antisense oligonucleotide targeted to gp90
gene by metacyclic trypomastigotes results in diminished steady-state
levels of gp90 mRNA. Parasites were incubated with the indicated
concentrations of fluorescein-labeled antisense oligonucleotide PS2,
fixed in paraformaldehyde, and analyzed by flow cytometry (A). Total
RNA extracted from parasites either untreated (—) or treated with
oligonucleotide PS2 was fractionated on formaldehyde-containing 1%
agarose gels, transferred to a nylon membrane, and probed succes-
sively with the 32P-labeled insert of the gp90 cDNA clone and the
b-tubulin coding sequence (B).
VOL. 69, 2001 T. CRUZI gp90 AND INFECTIVITY 357
sense oligonucleotides targeted to the gp90 gene. This lack of
inhibition on the genes encoding gp35/50 molecules was ex-
pected, for these belong to the mucin gene family (5, 9), quite
distinct from that comprising the gp90 gene. However, the
possibility existed that the expression of gp82, a metacyclic
trypomastigote stage-specific glycoprotein with adhesive prop-
erties (15), was altered, provided that the genes coding for
gp82 and gp90 are members of the same multigene family (2).
When that undesired inhibitory effect was precluded by design-
ing antisense oligonucleotides based on sequences of the gp90
gene with a minimal homology with the gp82 gene (Fig. 2),
gp90 expression was specifically diminished (Fig. 3A and 4).
On the other hand, treatment of metacyclic trypomastigotes
with antisense oligonucleotides with sequences common to the
gp90 and gp82 genes affected the expression of both molecules
(Fig. 3D).
We have found that oligonucleotides targeted to the gp90
gene are taken up by metacyclic trypomastigotes in a dose-
dependent manner (Fig. 7A) and appear to concentrate in the
parasite nucleus (data not shown). This results in reduced
levels of steady-state gp90 mRNA in oligonucleotide-treated
parasites (Fig. 7B).
If the expression of gp90 is specifically inhibited in metacy-
clic trypomastigotes treated with antisense oligonucleotides
and this leads to an increase in parasite infectivity, it is rea-
sonable to assume that gp90 is playing a modulatory role in the
process of host cell invasion. How could gp90 negatively affect
the infectivity of metacyclic trypomastigotes? We had previ-
ously postulated that gp82 plays a key role in host cell invasion
by inducing a Ca21 response both in the target cell and in the
parasite (17), an event that is required for parasite internal-
ization (6, 12, 21). As gp90 is also a cell adhesion molecule, the
presence of high levels of this molecule on the parasite surface
could impair the binding of gp82 to target cells. In that case,
the reduction in gp90 levels could increase the gp82-mediated
interaction of metacyclic trypomastigotes with host cells, lead-
ing to increased internalization. Our present resuls are in ac-
cord with this proposition.
We have recently mapped the host cell binding site of gp82
(10). It is located in the C-terminal domain of the molecule, in
a region not equivalent to the gp90 C-terminal domain, which
contains the host cell binding site. Consistent with this, r-gp90
but not r-gp82, each containing the C-terminal region of the
molecule, was capable of inhibiting the adhesion of native gp90
to HeLa cells (Fig. 1). Taken together, the present data and
our previous findings suggest that gp90 and gp82 interact with
distinct host cell receptors. Binding of gp82 to its receptor
induces an increase in the internal Ca21 concentration in host
cells. On the other hand, in metacyclic trypomastigotes, the
gp82-parasite interaction triggers a signaling cascade that in-
volves activation of a protein tyrosine kinase and culminates in
Ca21 mobilization (7, 29). By contrast, binding of gp90 to its
receptor is unable to induce the Ca21 response either in the
host cell or in the parasite (17), so that this interaction is
unproductive as far as cell invasion is concerned.
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